Navigation Links
GENova and TheraGlass in advanced negotiations
Date:9/16/2009

NEW YORK, Sept. 16 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB.) - GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

TheraGlass, classified as a medical device, interacts with the body's tissues to stimulate cell growth and provide vital anti-bacterial, structural, and regenerative proteins. It is entirely non-toxic and is reabsorbed and excreted through the body's natural metabolic processes.

The two companies are already actively exploring the possibilities and opportunities of combining TheraGlass IP with GENova's drug targets; which will create a brand new class of blockbuster therapeutic drugs for the treatment of cancer. This advancement is potentially worth significant amounts in royalty payments should GENova be successful in creating this new class of drug treatment.

The two companies have entered into an LOI for GENova to acquire a number of TheraGlass Ltd's patents, the deal is expected to close in Q4 and will see GENova significantly increase its overall value of its IP portfolio and thereby move closer to position itself as a possible takeover target for a major pharmaceutical company.

"The potential for augmenting cancer treatments with a regenerative product like TheraGlass is tremendous," says GENova CEO Aaron Whiteman. "While GENova's treatments destroy cancerous cells, TheraGlass can stimulate healthy cells to regenerate, thus expediting the healing process."

The two companies are mapping out the deal and plan on making the details of that deal public in the coming weeks.

About TheraGlass Ltd.

TheraGlass Ltd. has an exclusive international position for the commercialisation of sol-gel derived bioactive glass under the trade name TheraGlass. Discovered by Professo
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova Biotherapeutics forming academic partnerships
2. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
3. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
4. GENova gains access to Big Pharma
5. GENova appoints Dr. Wang Chong to Scientific Advisory Board
6. GENova appoints Dr. Philip Gould to Scientific Advisory Board
7. GENova issues clarifying press release
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova files patent for new breast cancer treatment
10. GENova appoints Director of Asian business development
11. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... , SATURDAY, July 30 (HealthDay News) -- A new study ... users obsessively check their devices for e-mails, social media and ... the United States and Finland, and found that they checked ... less than 30 seconds and involves opening the screen lock ...
... , Alexandria, VA Tobacco related disease is a ... studies suggest that "alternative" tobacco products may have supplanted ... African Americans, according to new research published in the ... Neck Surgery. While the tobacco-related disease ...
... In an effort to reduce the radiation dose delivered by ... a comprehensive CT radiation dose reduction program which has allowed ... at their facility, according to an article in the August ... Radiology . CT is an essential tool ...
... approaches to dietary counseling for obesity are heavily rooted ... the ability to choose healthy foods and portion ... comfort foods. According to preventive medicine ... supports a new counseling approach that views obesity as ...
... FRIDAY, July 29 (HealthDay News) -- Any time there,s a ... at a youth camp in Norway, the shootings of a ... -- one question seems to ring clearer than others: Why ... disturbed and capable of committing deadly violence? Psychiatrists and ...
... , SATURDAY, July 30 (HealthDay News) -- Daughters have ... mothers, but there is no similar effect the other ... that teens may have more impact on their parents ... The study included 343 mother-daughter pairs who completed ...
Cached Medicine News:Health News:Smartphones Really Are Habit-Forming: Study 2Health News:Effects of tobacco use among rural African American young adult males 2Health News:Community hospital implements successful CT radiation dose reduction program 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3Health News:Shootings Spark Interest in Spotting the Violence-Prone 2Health News:Shootings Spark Interest in Spotting the Violence-Prone 3
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... and BEDMINSTER, N.J., Aug. 31 QRxPharma (ASX: QRX ... symposium at the 13th World Congress of Pain on ...  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" ... an immediate-release Dual Opioid product for moderate to severe ...
... plc (LSE: SHP, NASDAQ: SHPGY ), ... for inflammatory bowel disease (IBD) fellowships at leading medical ... in 2011 and will provide a year of training ... completed a fellowship in gastroenterology. "We are ...
Cached Medicine Technology:QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 2QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 3Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 2Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 3
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: